CIS-(+/-)-3-CHLORO-1,3-DIMETHYL-N-[1-(4-BROMO-2-METHOXY-PHENYL)ETHYL]CYCLOBUTANECARBOXAMIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	WVFRCSYGBLGTBH-QEPHCTRTSA-N
Smiles	COc1cc(Br)ccc1C(C)NC(=O)[C@@]2(C)C[C@@](C)(Cl)C2
InChI	InChI=1S/C16H21BrClNO2/c1-10(12-6-5-11(17)7-13(12)21-4)19-14(20)15(2)8-16(3,18)9-15/h5-7,10H,8-9H2,1-4H3,(H,19,20)/t10?,15-,16+

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H21BrClNO2
Molecular Weight	374.7
AlogP	3.87
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	4.0
Polar Surface Area	38.33
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	21.0

Assay Description	Organism	Bioactivity
Fungicidal activity against Magnaporthe grisea isolate BV0-184 in rice seedlings seven days pre-treated with compound assessed as blast disease control at 0.2 ppm at 24 degC and 100% RH measured for 7 to 10 days after inoculation	Magnaporthe grisea	98.0 %
Fungicidal activity against Magnaporthe grisea isolate BV0-184 in rice seedlings seven days pre-treated with compound assessed as blast disease control at 0.8 ppm at 24 degC and 100% RH measured for 7 to 10 days after inoculation	Magnaporthe grisea	100.0 %
Fungicidal activity against Magnaporthe grisea isolate BV0-184 in rice seedlings seven days pre-treated with compound assessed as blast disease control at 3 ppm at 24 degC and 100% RH measured for 7 to 10 days after inoculation	Magnaporthe grisea	100.0 %
Inhibition of Magnaporthe grisea scytalone dehydratase	Magnaporthe grisea	0.03 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2251872

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).